Drug intelligence / Profile preview

bupropion + citalopram

Development stage
Unknown
Lead developer
GSK
Modality
Small Molecules
Administration
Oral
01

Overview

This is a combination therapy of two antidepressant medications, bupropion and citalopram. Bupropion is an aminoketone class antidepressant that primarily inhibits the reuptake of norepinephrine and dopamine, thereby increasing their levels in the brain. Citalopram is a selective serotonin reuptake inhibitor (SSRI) that increases serotonin levels by inhibiting its reuptake into presynaptic neurons. The combination is used off-label for treatment-resistant depression when monotherapy with either agent has been insufficient. Clinical studies suggest this combination can be more effective than switching to monotherapy in patients who have not responded to initial treatment[1][7]. Both drugs are taken orally.

Other names
bupropion + citalopramWellbutrin + Celexabupropion hydrochloride + citalopram hydrobromide
02

Targets

NET (Norepinephrine Transporter)DAT (Dopamine plasma membrane transport protein)SERT (Sodium-dependent serotonin transporter)

Beyond the preview

Go deeper on bupropion + citalopram.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on bupropion + citalopram.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call